,40 While the stimulation of CD8 T cells by ICIs have achieved unprecedented success in cancer immunotherapy, ICI efficacy against solid tumors remains limited and ICI-induced immune-related adverse events (irAE) can be severe.34 Here, CD8A is linked to cancer.